A young and dynamic pharma company which strives to support precious life. With dedicated team, it strives to create excellence in every arena by encouraging quality control, team work,training and employee satisfaction.
BLAZE TO BRILLIANCE
Globally Gliptin is emerging as the preferred line of treatment for managing Type-2 Diabetes, with once-a-day administration. Though the efficacy and safety of Gliptin is proven globally, it is vital that we establish the efficacy and safety of Gliptins in Indian patients. Your clinical observation will be essential in asserting the glycemic and vascular benefits of TENUVIA (Teneligliptin 20mg).
Tenuvia was launched with a single aim of addressing the void in Diabetes management. It addresses the 4th quadrant of diabetes management ie: Glycemic Variability. It is driven by the sole purpose of providing high quality and cost effective gliptin therapy to the Indian population. The great Indian dream has realized with the launch of Tenuvia. Tenuvia made an impact on the doctors mind immediately due to the wide availability and affordable price. By March 2015, 50000 patients were already on Tenuvia therapy with more patient experience being added on a daily basis. In April 2016, brand basket was expanded with combination therapy of Tenumet looking into the huge demand by prescribing doctors and patients.
1. Tenuvia was launched with a single aim of addressing the void in Diabetes management.
2. In April 2016, brand basket was expanded with combination therapy of Tenumet looking into the huge demand. PROMISE BEACON
1. A distribution network of more than 200 stockiest.
2. Tenuvia was launched in November, 2014.
ENGAGEMENT THAT ENTHRALLS
With pure intent of providing cost effective Gliptin in India, Precia Pharma are initiating a study; (EI-XPERT) Evaluation of Indian experience of efficacy and safety of Teneligliptin. The company would be enrolling 50,000 patients in this initiative, this activity will be carried out under the banner of PIAI – Precia India Academic Initiative. This program serves the purpose to collect primary data from 500 leading Endocrinologists / Diabetologists and Physicians who would actively participate through patient’s enrolment and who will be subsequently the author of academic paper which will be published in Index journals. This study is supported by an unrestricted educational grant from Precia Pharma Private Limited.
Scientist holding a molecular model of nanoparticle
The company provides innovative and superior quality products and services which lead to better patient care and thus supporting precious life. It wants to develop and deliver innovative products to ease the ailment and enhance the quality of life with a firm faith and belief in growing together. Precia Pharma promise to serve the Precious life.
The company aims to build value by delivering pharmaceutical and healthcare products, services and solutions in innovative and cost effective ways by setting the highest standards in service, reliability, safety and cost containment in our industry. And aspires to become a valued and preferred partner to the global healthcare industry.